Human KDR/NFAT-Luc Reporter Cell Line - HEK293

The Human KDR/NFAT-Luc Reporter Cell Line - HEK293 is an advanced in vitro model built upon the foundational Human Embryonic Kidney 293 (HEK293) lineage. HEK293 cells are widely favored in cellular biology for their stable adherent growth, epithelial morphology, and high amenability to complex genetic engineering. This specific reporter line is precisely modified to stably overexpress human Kinase Insert Domain Receptor (KDR), comprehensively known as Vascular Endothelial Growth Factor Receptor 2 (VEGFR2), which is the primary receptor tyrosine kinase responsible for mediating endothelial cell proliferation and angiogenesis. Alongside KDR, the cells contain a stably integrated firefly luciferase (Luc) reporter gene under the transcriptional control of multiple Nuclear Factor of Activated T-cells (NFAT) response elements. Biologically, when a VEGF ligand binds to the KDR receptor, it triggers the phospholipase C-γ (PLC-γ) signaling cascade, leading to a rapid release of intracellular calcium. This calcium surge activates the phosphatase calcineurin, which in turn dephosphorylates NFAT, allowing it to translocate into the nucleus. The active NFAT complex then binds to the engineered promoter, driving the transcription of the luciferase enzyme to produce a robust, highly quantifiable bioluminescent signal.

The stimulus-responsive nature of this engineered cell line makes it a premier tool for vascular biology research and targeted oncology drug discovery pipelines. In laboratory settings, the dynamic bioluminescent output serves as a highly sensitive, real-time metric for quantifying VEGF/KDR pathway activation. This establishes an ideal platform for the high-throughput screening (HTS) of novel anti-angiogenic therapeutics, including small-molecule tyrosine kinase inhibitors (TKIs), recombinant neutralizing antibodies, and soluble decoy receptors designed to suppress tumor-induced blood vessel formation. Because the KDR signaling axis is a major driver of pathological angiogenesis in solid tumors, macular degeneration, and various inflammatory conditions, accurately monitoring its activation is critical for therapeutic development. By enabling researchers to directly measure functional receptor activation and intracellular calcium signaling without relying on labor-intensive, low-throughput diagnostic assays like Western blotting for phosphorylated proteins, this reporter line significantly accelerates the preclinical development and validation of vascular-targeted pharmacological agents.